|
EYA3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.53950202480746E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.74410486053489E-11 |
| Normal-vs-Stage2 |
6.38679997777558E-10 |
| Normal-vs-Stage3 |
2.89102075612391E-12 |
| Normal-vs-Stage4 |
6.15951734062037E-13 |
| Stage1-vs-Stage2 |
6.860600E-01 |
| Stage1-vs-Stage3 |
1.903550E-01 |
| Stage1-vs-Stage4 |
5.541700E-02 |
| Stage2-vs-Stage3 |
5.976600E-01 |
| Stage2-vs-Stage4 |
3.015200E-01 |
| Stage3-vs-Stage4 |
5.061000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.27595761418343E-12 |
| Normal-vs-AfricanAmerican |
4.24620000000209E-05 |
| Normal-vs-Asian |
1.00699448779551E-11 |
| Caucasian-vs-AfricanAmerican |
2.372600E-01 |
| Caucasian-vs-Asian |
2.929800E-01 |
| AfricanAmerican-vs-Asian |
8.178200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.30211422042248E-13 |
| Normal-vs-Female |
9.84734516151775E-12 |
| Male-vs-Female |
1.055960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.02450320133607E-11 |
| Normal-vs-Age(41-60Yrs) |
4.64739358108091E-12 |
| Normal-vs-Age(61-80Yrs) |
9.67226299053436E-13 |
| Normal-vs-Age(81-100Yrs) |
1.965190E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.548600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.053790E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.430400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.930000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.407800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.067800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.249500E-02 |
| Classical-VS-Follicular |
2.487500E-02 |
| Classical-VS-Other |
1.235620E-01 |
| Classical-VS-Normal |
1.76719971989314E-10 |
| Tall-VS-Follicular |
6.632400E-01 |
| Tall-VS-Other |
5.396400E-01 |
| Tall-VS-Normal |
1.12290177156638E-11 |
| Follicular-VS-Other |
4.451800E-01 |
| Follicular-VS-Normal |
3.98314714544767E-12 |
| Other-VS-Normal |
1.563520E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.11026768176725E-12 |
| Normal-vs-N1 |
3.68294283958903E-12 |
| N0-vs-N1 |
3.124800E-01 |
|
|
